TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1492847
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available granules containing 600 mg ibuprofen
Study: 3884358
Drug: S-R theophylline
Normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-R theophylline preparation given once each night (mean 11.2 mg/kg/day)
Study: 3884358
Drug: S-R aminophylline
Normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-R aminophylline preparation every 12 h (mean 10.3 mg theophylline/kg/day)
Study: 26696365
Drug: PPI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI group (lansoprazole 15 mg twice daily for 2 months)
Study: 27428202
Drug: Atazanavir/ritonavir (ATV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (ATV/r) monotherapy
Study: 24445981
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (40 mg/kg)
Study: 16109088
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg alendronate, taken once a week for 6 weeks
Study: 17488902
Drug: Chloroquine 50
Normalized name: chloroquine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 50 mg/kg
Study: 3287881
Drug: Diltiazem (10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (10-mg intravenous bolus followed by 15 mg/hr intravenous infusion during 72 hours, followed by 4 X 60 mg during 21 days)
Study: 24914489
Drug: Standard cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioral group therapy (CBGT)
Study: 21908466
Drug: Tablets moistened
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets moistened with 3 ml of normal saline
Study: 21908466
Drug: Tablets moistened
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets moistened with 3 ml of 5% acetic acid
Study: 21908466
Drug: Dry tablets
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry tablets
Study: 18288734
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of mononuclear bone marrow cells (MBMC)
Study: 11119395
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d
Study: 8936545
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 1 mg.kg‐1 without fentanyl
Study: 8936545
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam 0.4 mg.kg‐1 without fentanyl
Study: 8936545
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 1 mg.kg‐1 with fentanyl 0.75 microgram.kg‐1 i.v.
Study: 8936545
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam 0.4 mg.kg‐1 with fentanyl 0.75 microgram.kg‐1 i.v.
Study: 29438373
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg per day, per os; days 1-14; 21 days per cycle)
Study: 15353389
Drug: Risperidone (0.5-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5-1.5 mg/day)
Study: 15353389
Drug: Haloperidol (0.5-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5-1.5 mg/day)
Study: 3119647
Drug: hCG/hMG treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG/hMG treatment (2500 IU hCG twice a week + 150 IU hMG three times a week for 13 weeks)
Study: 3119647
Drug: Placebo (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl only, same injection schedule)
Study: 3119647
Drug: hCG/hMG treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG/hMG treatment
Study: 27926631
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific treatment (group 3)
Study: 20526206
Drug: BI 2536
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 2536 (200 mg on day 1)
Study: 20526206
Drug: BI 2536
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 2536 (50 or 60 mg on days 1 to 3)
Study: 18468955
Drug: 6000 mg
Normalized name: psyllium 6000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6000 mg chloride potassium dissolved in grape juice for 28 consecutive days
Study: 16177196
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg calcium as carbonate, 3 times/d with meals)
Study: 16177196
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules identical in appearance
Study: 10047688
Drug: Chinese Hamster
Normalized name: Recombinant human antigen-specific polyclonal antibody (pAb) against RhD antigen expressed in Chinese hamster ovary cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Hamster Ovary cell drived HB vaccine (CDV)
Study: 10047688
Drug: Plasma drived
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma drived HB vaccine (PDV)
Study: 8721550
Drug: High-dose ganciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ganciclovir
Study: 8721550
Drug: Combination foscarnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination foscarnet and ganciclovir
Study: 1376845
Drug: Isradipine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (0.4 mg)
Study: 1376845
Drug: Nifedipine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (2.0 mg)
Study: 6344896
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid (mean daily dose 278 mg, range 125-500 mg)
Study: 6344896
Drug: Conventional diuretics
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diuretics (mainly thiazide)
Study: 6344896
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid and Conventional diuretics
Study: 26554360
Drug: High-dose target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose target-controlled naloxone infusion
Study: 19302911
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of anagrelide (2 mg/d, taken as 4 capsules)
Study: 19302911
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of anagrelide
Study: 19302911
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of anagrelide
Study: 9558688
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 mg/day)
Study: 2944268
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose cyproteronacetate plus lisuride (DoperginR)
Study: 31230494
Drug: Direct release
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct release Mg2+ supplement (one phase)
Study: 31230494
Drug: Delayed release
Normalized name: GRANULES, DELAYED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed release Mg2+ supplement (two phases)
Study: 20377925
Drug: Wagyu beef
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wagyu beef (100 g)
Study: 20377925
Drug: Kangaroo meat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo meat (100 g)
Study: 12050252
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg daily for 2 years
Study: 11148939
Drug: Standardized, nonpunitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized, nonpunitive medication‐use variance process
Study: 11148939
Drug: Traditional, multitiered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional, multitiered incident‐reporting system for medication errors
Study: 9289431
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of ovarian neoplasms
Study: 6120389
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral prednisolone with azathioprine
Study: 6120389
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral prednisolone with azathioprine
Study: 22340989
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone and local betamethasone injected at the tongue base
Study: 23440680
Drug: Fenoldopam (0.025-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam (0.025-0.3 g/kg/min)
Study: 16291413
Drug: Solifenacin 10
Normalized name: solifenacin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 10 mg QD for 10 days during the second cycle
Study: 12479423
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with a 3 ml h(‐1) continuous infusion of fentanyl (2 microg) and bupivacaine (0.125%) for the first 3 days, with patient-controlled analgesia allowing an additional 5 ml of the same solution when pain score > 4.
Study: 7629581
Drug: Protocol 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 1: infusion of 201Tl (111 MBq), insulin (5 U), potassium (10 mEq) in 10% glucose solution (250 ml)
Study: 7629581
Drug: Protocol 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 2: infusion of 201Tl (111 MBq), potassium (10 mEq), insulin (5 U) in 5% glucose (250 ml)
Study: 7033847
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg twice daily for 14 days
Study: 26082085
Drug: Alginate-hydrogel in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate-hydrogel in combination with standard medical therapy
Study: 23883807
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) nasal spray at 110 μg once daily for 12 weeks
Study: 19297788
Drug: Alendronate (bisphosphonate),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (bisphosphonate), once-weekly treatment for 6 months
Study: 19297788
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, once-weekly for 6 months
Study: 17194255
Drug: Placebo (PLA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA; 34 g dextrose)
Study: 17194255
Drug: Beta-alanine (b‐Ala;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (b‐Ala; 1.6 g b‐Ala plus 34 g dextrose)
Study: 17194255
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CrM; 5.25 g CrM plus 34 g dextrose)
Study: 17194255
Drug: Beta-alanine plus
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine plus creatine (CrBA; 5.25 g CrM plus 1.6 g b‐Ala plus 34 g dextrose)
Study: 12692611
Drug: Calcium phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium phosphate mouth rinse (Caphosol) with fluoride treatments
Study: 12692611
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of fluoride rinsing and placebo tray treatments
Study: 10584132
Drug: 200 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m2 amifostine i.v., 30 minutes before radiation
Study: 1877263
Drug: sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 2 g q12h for five doses with ciprofloxacin 750 mg concurrently (Treatment A)
Study: 1877263
Drug: ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 750 mg administered two hours before the fifth dose of sucralfate (Treatment B)
Study: 1877263
Drug: ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 750 mg six hours before the fifth dose of sucralfate (Treatment C)
Study: 1877263
Drug: ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 750 mg alone (Treatment D)
Study: 6311789
Drug: Ceftazidime (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (single dose preoperatively)
Study: 6311789
Drug: Cefotaxime (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (three doses perioperatively)
Study: 26320001
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care including medication (n = 60)
Study: 19874474
Drug: INR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: INR and prior doses
Study: 15984968
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg od
Study: 15984968
Drug: cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisapride 20 mg bid
Study: 1672481
Drug: Celiprolol (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200, 400, 600 mg once daily)
Study: 1672481
Drug: Propranolol (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (total daily dose 80, 160, 320 mg twice daily)
Study: 31629570
Drug: dPly/PhtD vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: dPly/PhtD vaccine (10 µg dPly and 10 µg PhtD) co-administered with 13-valent PCV (PCV13)
Study: 31629570
Drug: Placebo co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo co-administered with 13-valent PCV (PCV13)
Study: 15836887
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rimonabant
Study: 21869692
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rimonabant
Study: 12621596
Drug: Pentagastrin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentagastrin (0.2 micro g/kg)
Study: 12621596
Drug: TRH (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (600 or 1200 micro g)
Study: 12621596
Drug: Pentagastrin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentagastrin (0.1 micro g/kg)
Study: 11188493
Drug: 0.56 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.56 g/kg of alcohol
Study: 1415022
Drug: Interferon-alpha (IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (IFN alpha) therapy
Study: 31130429
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for symptomatic vertebral artery stenosis
Study: 25686399
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral tegafur-uracil (UFT) at 600 mg/day
Study: 25686399
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no UFT treatment)
Study: 25686399
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral tegafur-uracil (UFT)
Study: 21852010
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy plus radiation
Study: 15266763
Drug: Clotrimazole 200
Normalized name: clotrimazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 200 mg vaginal tablets
Study: 9875578
Drug: Live recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live recombinant canarypox-HIV-1 vaccine (given at days 0, 7, 14, and 21)
Study: 9875578
Drug: Subunit gp120
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit gp120 vaccine (given at days 28 and 84)
Study: 9875578
Drug: Unprimed controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unprimed controls (received two doses of subunit vaccine)
Study: 7612066
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate gel (Virudermin Gel)
Study: 2116311
Drug: Felodipine 5-10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5-10 mg b.i.d.
Study: 27611958
Drug: Mobile app
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile app treatment (Tät®) focused on pelvic floor muscle training (PFMT)
Study: 27611958
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (postponed treatment)
Study: 21649839
Drug: Fixed-dose amlodipine/olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose amlodipine/olmesartan medoxomil (AML/OM) 5/20 mg, uptitrated to AML/OM 5/40 mg and 10/40 mg
Study: 21649839
Drug: Fixed-dose amlodipine/olmesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose amlodipine/olmesartan medoxomil + hydrochlorothiazide (HCTZ) 10/40+25 mg
Study: 12673155
Drug: Ginseng (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (400 mg.d‐1 of G115; equivalent to 2 g of Panax ginseng C.A. Meyer root material)
Study: 1988829
Drug: Intravenous vidarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vidarabine (30 mg/kg/day for 10 days)
Study: 3987791
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg moclobemide
Study: 6388247
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg moclobemide
Study: 3987791
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg moclobemide
Study: 27055414
Drug: 0.1% cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops, once daily
Study: 15852492
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus (saffron) 30 mg/day
Study: 14607390
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (sertraline, phenelzine, or bupropion) for 8 weeks
Study: 12884887
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg/d) plus buprenorphine (12 mg/d)
Study: 12884887
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg/d) plus methadone (65 mg/d)
Study: 1444728
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg/d)
Study: 12884887
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus buprenorphine (12 mg/d)
Study: 12884887
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus methadone (65 mg/d)
Study: 6355500
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with silver sulfadiazine cream
Study: 27499517
Drug: Ocriplasmin 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin 0.125 mg
Study: 16006259
Drug: Vitamin supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplementation (folic acid 5 mg, pyridoxine 40 mg, cyanocobalamin 1 mg once daily for 3 months)
Study: 16006259
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin treatment (control group)
Study: 10390316
Drug: Oral nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nimodipine (30 mg every 6 hours)
Study: 8683244
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) cisplatin 100 mg/m2
Study: 8683244
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) cisplatin 50 mg/m2
Study: 30344172
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia with tramadol
Study: 30344172
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia with hydromorphone
Study: 25247318
Drug: Erlotinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib dose escalation (150 mg, increasing by 50 mg every 2 weeks, maximum 250 mg)
Study: 25247318
Drug: Standard-dose erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose erlotinib (100 mg per day)
Study: 25247318
Drug: Erlotinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib dose escalation
Study: 25247318
Drug: Standard-dose erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose erlotinib
Study: 21809168
Drug: Aripiprazole (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (10-30 mg/day)
Study: 16180181
Drug: Propafenone (150‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (150‐300 mg)
Study: 16180181
Drug: Amiodarone (150‐450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (150‐450 mg)
Study: 12187545
Drug: L-arginine glutamate
Normalized name: L-Arginine L-glutamate
DrugBank: Arginine glutamate (DB13207)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine glutamate (6 g) plus yohimbine HCl (6 mg)
Study: 12187545
Drug: yohimbine alone
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: yohimbine alone (6 mg)
Study: 10442189
Drug: Postoperative RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative RT and concomitant bolus FU administration with additional chemotherapy (FU 600 mg/m2/week x 6 + LV 500 mg/m2/week x 6) followed by pelvic RT with FU (400 mg/m2) during RT
Study: 7617181
Drug: Copolymer 1
Normalized name: glatiramer (copolymer 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copolymer 1 (20 mg daily subcutaneous injection for 2 years)
Study: 2774639
Drug: Grenz rays
Normalized name: Ray Dol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grenz rays administered once weekly for 4 weeks
Study: 30699155
Drug: Treatment-as-usual training
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual training
Study: 25792303
Drug: Early individualised
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early individualised manipulative rehabilitation (twice a week for 4 weeks, 30 minutes per session)